...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Scandinavian journal of immunology. >Humoral and Cellular Responses to a Single Dose of Fendrix in Renal Transplant Recipients with Non-response to Previous Hepatitis B Vaccination
【24h】

Humoral and Cellular Responses to a Single Dose of Fendrix in Renal Transplant Recipients with Non-response to Previous Hepatitis B Vaccination

机译：对肾移植受者在肾移植受者的单剂量和细胞反应对先前的乙型肝炎疫苗接种的肾移植受者的反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Approximately 70% of kidney transplant recipients are non-responders to conventional hepatitis B virus (HBV) vaccines. We examined whether Fendrix T, an HBV vaccine containing 3-O-desacyl-4'-monophosphoryl lipid A (MPL) as adjuvant, could induce HBV immunity in these patients and compared their vaccination efficacy with healthy controls tested previously by the same assays. We selected 35 kidney transplant recipients who had been vaccinated at least thrice against HBV but had never displayed anti-HBs antibodies. We re-assessed their anti-HBs antibody titres and further determined cellular HBV immunity by proliferation assay and interferon (IFN)-gamma ELISpot. Seventeen recipients did neither display humoral nor cellular immunity and could be tested prior to and at month 1 after vaccination. Of note, HLA antigens associated with non-response to HBV vaccination (HLA-DRB1*03 and HLA-DQB1*02) were over-represented in these 17 recipients. At month 1 after a single vaccination with Fendrix (TM), we observed a significant increase in anti-HBs antibodies (P = 0.02). In seven of 17 recipients, we detected anti-HBs antibodies >= 10 IU/l (10-264), in four HBV-specific lymphocyte proliferation (stimulation index of 2.6-8.7) and in one specific IFN-gamma responses (12 spots increment). The vaccination response to Fendrix (TM) was significantly higher (P = 0.035) than the response to HBVaxPro (TM) in young healthy controls. In summary, the results show that a single vaccination with Fendrix could already induce HBV-specific humoral and/or cellular responses in ten of 17 kidney transplant patients. Thus, Fendrix (TM) appears as an efficient vaccine in this patient cohort.
机译：大约70％的肾移植受者是常规乙型肝炎病毒（HBV）疫苗的非响应者。我们检查了Fendrix T是否含有3-脱乙酰-4'-单磷虾脂质A（MPL）作为佐剂的HBV疫苗，可以在这些患者中诱导HBV免疫力，并将其与先前测试的健康对照进行了比较了它们的疫苗接种功效。我们选择了35名肾脏移植受者，他们至少接种了抗HBV接种，但从未显示过抗HBS抗体。我们重新评估其抗HBS抗体滴度，并通过增殖测定和干扰素（IFN）-Gamma ELISPOT进一步确定细胞HBV免疫。十七个接受者既不表达体液和细胞免疫，可以在接种疫苗后1月1日之前测试。值得注意的是，在这17个受体中过度表示与HBV疫苗接种的非反应（HLA-DRB1 * 03和HLA-DQB1 * 02）相关的HLA抗原。在与Fendrix（TM）进行一次疫苗接种后的第1次，我们观察到抗HBS抗体的显着增加（P = 0.02）。在17名受者中，我们检测到抗HBS抗体> = 10 IU / L（10-264），以四种HBV特异性淋巴细胞增殖（刺激指数为2.6-8.7），并在一个特定的IFN-Gamma响应中（12个斑点增量）。对Fendrix（TM）的疫苗接种反应显着高于年轻健康对照对HBVaxPro（TM）的响应显着更高（p = 0.035）。总之，结果表明，与Fendrix的单一疫苗接种可能已经诱导17个肾移植患者中的十种中的HBV特异性的体液和/或细胞反应。因此，Fendrix（TM）在该患者队列中表现为有效的疫苗。

著录项

  • 来源
  • 作者

    Lindemann M.; Zaslavskaya M.; Fiedler M.; Wilde B.; Heinemann F. M.; Heinold A.; Horn P. A.; Witzke O.;

  • 作者单位

    Univ Hosp Essen Inst Transfus Med Virchowstr 179 D-45147 Essen Germany;

    Univ Hosp Essen Inst Transfus Med Virchowstr 179 D-45147 Essen Germany;

    Univ Hosp Essen Inst Virol Essen Germany;

    Univ Hosp Essen Dept Nephrol Essen Germany;

    Univ Hosp Essen Inst Transfus Med Virchowstr 179 D-45147 Essen Germany;

    Univ Hosp Essen Inst Transfus Med Virchowstr 179 D-45147 Essen Germany;

    Univ Hosp Essen Inst Transfus Med Virchowstr 179 D-45147 Essen Germany;

    Univ Hosp Essen Dept Nephrol Essen Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号